Veru Inc. Announces Pipeline Shift to Advance Sabizabulin for Pancreatic Cancer

What Happened
Veru Inc. announced on September 8, 2026 (via an 8‑K and attached press release) that, based on new positive preclinical data and prior studies, it is expanding development of its oral microtubule‑targeting agent sabizabulin as a potential treatment for patients with KRAS‑mutant metastatic pancreatic cancer that is resistant to daraxonrasib (RASONQUE™). At the same time, Veru said it will discontinue exploration of sabizabulin for chronic inflammation related to atherosclerotic cardiovascular disease.

Key Details

• Announcement date: September 8, 2026 (press release attached as Exhibit 99.1 to the 8‑K).
• Drug: sabizabulin — described as an oral, novel, microtubule‑targeting agent.
• New focus: KRAS‑metastatic pancreatic cancer cell lines that showed resistance to daraxonrasib (RASONQUE™, a Revolution Medicines trademark).
• Program change: Veru will no longer pursue sabizabulin for chronic inflammation related to atherosclerotic cardiovascular disease.

Why It Matters
This is a strategic pipeline decision: Veru is reallocating sabizabulin development toward a specific oncology niche (KRAS‑mutant, daraxonrasib‑resistant metastatic pancreatic cancer) where new preclinical data suggest activity. For investors, the change narrows the drug’s target indication—which can concentrate resources on a potentially higher‑value oncology opportunity—but also ends pursuit of a cardiovascular/anti‑inflammatory indication previously under consideration. The filing contains no new financial results or clinical trial timelines; investors should watch for follow‑up updates on planned trials, regulatory strategy, and any partnership or financing announcements.